

XII ANNUAL Ri.MED SCIENTIFIC SYMPOSIUM

# Cancer Immunotherapy

Recent progress and future challenges

FRIDAY  
OCTOBER  
12<sup>th</sup> 2018

Palazzo dei Normanni  
Sala Piersanti Mattarella  
Piazza del Parlamento  
Palermo - Italy

8.30 am SYMPOSIUM REGISTRATION

9.00 am **Introduction and Ri.MED Overview**

Dario A. A. Vignali, Ph.D. - *Scientific Director, Fondazione Ri.MED*  
Alessandro Padova, Ph.D. - *Director General, Fondazione Ri.MED*  
Angelo Luca, M.D. - *Director, IRCSS ISMETT*

## SESSION I

9.30 am **The Tumor Immune Microenvironment: Inhibitory Mechanisms and Therapeutic Opportunities**

Keynote speaker: Dario A. A. Vignali, Ph.D.

10.15 am **Using Genomics to understand T Cell Dynamics in the Tumor Microenvironment**

Ana C. Anderson, Ph.D.

10.45 am COFFEE BREAK

## SESSION II

11.05 am **Targeting Regulatory T Cells for Therapeutic Gain: Means and Mechanisms**

Sergio A. Quezada, Ph.D.

11.35 am **Unwinding CD137 and Interleukin-8 in Cancer Immunotherapy**

Ignacio Melero, M.D., Ph.D.

12.05 am **Targeting the differential Function of Tumor infiltrating B Cells in solid Tumors to increase Immunotherapeutic Efficacy for Cancer Patients**

Tullia Bruno, Ph.D.

12.35 pm LUNCH

## SESSION III

1.15 pm **Lesson from Cancer: "Flipping" over Monocytes into Immune-suppressive Cells**

Vincenzo Bronte, M.D., Ph.D.

1.45 pm **TILs to TCRs: Adoptive T Cell Therapy Strategies for Poorly Immunogenic Cancers**

Udai S. Kammula, M.D., FACS

2.15 pm COFFEE BREAK

## SESSION IV

2.35 pm **Novel I-O Combination: the Role of Anti-LAG-3 and Adenosine Pathway Inhibitors**

Paolo Ascierto, M.D.

3.05 pm **Development and Integration of Immunotherapy into the Management of Head and Neck Cancer: Dangers and Opportunities**

Keynote speaker: Robert L. Ferris, M.D., Ph.D.

3.50 pm CLOSING REMARKS

## KEYNOTE SPEAKERS:

**Dario A. A. Vignali, Ph.D.**

*Scientific Director, Fondazione Ri.MED*  
*The Frank Dixon Chair in Cancer Immunology,*  
*Vice Chair and Professor of Immunology, Department of Immunology,*  
*University of Pittsburgh School of Medicine, and Co-Leader, Cancer*  
*Immunology and Immunotherapy Program,*  
*Co-Director, Tumor Microenvironment Center, UPMC Hillman Cancer Center,*  
*Pittsburgh, USA*

**Robert L. Ferris, M.D., Ph.D.**

*Director, UPMC Hillman Cancer Center*  
*Hillman Professor of Oncology*  
*Associate Vice-Chancellor for Cancer Research*  
*Co-Director, Tumor Microenvironment Center*  
*Professor of Otolaryngology, of Immunology, and of Radiation Oncology,*  
*Pittsburgh, USA*

## SPEAKERS:

**Ana C. Anderson, Ph.D.**

*Associate Professor of Neurology, Broad Institute, Harvard Medical School*  
*and Brigham and Women's Hospital, Boston, USA*

**Paolo Ascierto, M.D.**

*Director, Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy,*  
*National Tumor Institute Fondazione "G. Pascale", Naples, Italy*

**Vincenzo Bronte, M.D., Ph.D.**

*Professor, Department of Medicine, Verona University Hospital, Verona, Italy*

**Tullia Bruno, Ph.D.**

*Research Assistant Professor Department of Immunology University of*  
*Pittsburgh, Pittsburgh, USA*

**Ignacio Melero, M.D., Ph.D.**

*Co-Director, Immunology and Immunotherapy Service*  
*Senior Researcher, Clinica Universidad de Navarra*  
*Senior Investigator, Centro de investigación Médica Aplicada (CIMA),*  
*Pamplona, Spain*

**Sergio Quezada, Ph.D.**

*Group Leader, Immune Regulation and Tumor Immunotherapy Lab*  
*University College London Cancer Institute, London, UK*

**Udai S. Kammula, M.D., FACS**

*Director, Solid Tumor Cell Therapy Program, UPMC Hillman Cancer Center,*  
*Pittsburgh, USA*

**CHAIRMAN: Dario A. A. Vignali, Ph.D.**